|
Powered by Cell Signaling Technology |
Site Information |
---|
MRtLsAHsVPNISGA SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 4769719 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Treatments: |
References | |
---|---|
Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia
28852199 Curated Info |
|
Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6
26060331 Curated Info |
|
Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86
23567750 Curated Info |
|
Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622 Curated Info |
|
Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6
21659605 Curated Info |
|
Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079 Curated Info |
|
Zhou J (2009) CST Curation Set: 7426; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info |
|
Zhou J (2009) CST Curation Set: 7425; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info |